- Home
- SKYE vs SSSS Comparison
SKYE vs SSSS Comparison
Compare SKYE & SSSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- SSSS
- Stock Information
- Founded
- SKYE 2012
- SSSS 2010
- Country
- SKYE United States
- SSSS United States
- Employees
- SKYE N/A
- SSSS N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- SSSS Finance: Consumer Services
- Sector
- SKYE Health Care
- SSSS Finance
- Exchange
- SKYE Nasdaq
- SSSS Nasdaq
- Market Cap
- SKYE 108.3M
- SSSS 118.1M
- IPO Year
- SKYE N/A
- SSSS N/A
- Fundamental
- Price
- SKYE $4.12
- SSSS $5.05
- Analyst Decision
- SKYE Buy
- SSSS Buy
- Analyst Count
- SKYE 6
- SSSS 2
- Target Price
- SKYE $18.67
- SSSS $6.00
- AVG Volume (30 Days)
- SKYE 166.3K
- SSSS 182.5K
- Earning Date
- SKYE 11-07-2024
- SSSS 11-07-2024
- Dividend Yield
- SKYE N/A
- SSSS N/A
- EPS Growth
- SKYE N/A
- SSSS N/A
- EPS
- SKYE N/A
- SSSS N/A
- Revenue
- SKYE N/A
- SSSS $5,903,895.00
- Revenue This Year
- SKYE N/A
- SSSS N/A
- Revenue Next Year
- SKYE N/A
- SSSS $6.05
- P/E Ratio
- SKYE N/A
- SSSS N/A
- Revenue Growth
- SKYE N/A
- SSSS 5.43
- 52 Week Low
- SKYE $1.44
- SSSS $3.32
- 52 Week High
- SKYE $19.41
- SSSS $5.44
- Technical
- Relative Strength Index (RSI)
- SKYE 35.19
- SSSS 57.01
- Support Level
- SKYE $4.32
- SSSS $4.81
- Resistance Level
- SKYE $5.67
- SSSS $5.44
- Average True Range (ATR)
- SKYE 0.49
- SSSS 0.27
- MACD
- SKYE -0.17
- SSSS -0.03
- Stochastic Oscillator
- SKYE 2.65
- SSSS 51.85
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About SSSS SuRo Capital Corp.
SuRo Capital Corp is a non-diversified closed-end management investment company. The company's investment objective is to maximize its portfolio's total return, principally by seeking capital gains on its equity and equity-related investments.